Approvable letter Advair COPD

GlaxoSmithKline PLC
16 December 2002


Issued: 07.00 Tuesday 17th December, London



GlaxoSmithKline Receives US Approvable Letter for Advair(TM) for the Treatment 
                 of Chronic Obstructive Pulmonary Disease



GlaxoSmithKline today announced it has received an approvable letter from the
U.S. Food and Drug Administration (FDA) for Advair(TM) Diskus(TM), which is under
review for the treatment of chronic obstructive pulmonary disease (COPD). An
approvable letter had previously been received in March this year.

GlaxoSmithKline is working with the FDA to clarify and resolve outstanding
issues.

S M Bicknell

Company Secretary

17 December 2002





About GSK:

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.

Under the safe harbor provisions of the US Private Securities Litigation Reform
Act of 1995, GlaxoSmithKline cautions investors that any forward-looking
statements or projections made by GSK, including those made in this news
release, are subject to risks and uncertainties that may cause actual results to
differ materially from those projected. Factors that may affect the company's
operations are discussed in the section "Cautionary factors that may affect
future results" in GSK's results announcement for the year ended 31 December
2001, filed with the U.S. Securities and Exchange Commission."


For company information, visit GSK on the World Wide Web at http://www.gsk.com


Enquiries:


UK Media enquiries:                     Martin Sutton            [phone]

                                        Alan Chandler            [phone]

                                        Siobhan Lavelle          [phone]


US Media enquiries:                     Nancy Pekarek            [phone]

                                        Mary Anne Rhyne          [phone]

                                        Patricia Seif            [phone]


European Analyst/Investor enquiries:    Duncan Learmouth         [phone]

                                        Philip Thomson           [phone]

                                        Anita Kidgell            [phone]


US Analyst/ Investor enquiries:         Frank Murdolo            [phone]

                                        Tom Curry                [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange